Search Results

Boston Scientific's Jactax DES Shows Promise in First-Human-Use Study

April 20, 2010—Eberhard Grube, MD, et al have published 9-month outcomes of the JACTAX drug-eluting stent trial in the Journal of the American College of Cardiology: Cardiovascular Interventions (2010;3:431–438).

Five-Year Data Presented for Biosensors' Axxess Bifurcation DES at TCT

November 8, 2011—Biosensors International Group, Ltd. (Singapore) announced that Professor Eberhard Grube, MD, presented final results of the AXXESS PLUS trial at the Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco, California.

Millipede Announces Successful First Use of the Iris Complete Annuloplasty Ring

May 12, 2017—Millipede, Inc. announced that it has successfully completed its first clinical use of its transcatheter Iris complete annuloplasty ring.

TAVI Studies Published

July 19, 2011—Two studies of transcatheter aortic valve implantation (TAVI) were published in the Journal of the American College of Cardiology: Cardiovascular Interventions.

European Registries Confirm Benefits of Medtronic's CoreValve System

May 25, 2010—Medtronic, Inc. (Minneapolis, MN) announced that new European data from five national clinical registries studying transcatheter aortic valve implantation (TAVI) were presented at the EuroPCR 2010 conference in Paris.

Claret Medical's Montage 2 Embolic Filter System Receives CE Mark Approval

February 27, 2013—Claret Medical, Inc. (Santa Rosa, CA) announced that the Montage 2 dual filter system received CE Mark approval.

Invatec's In.Pact Falcon Receives CE Mark

March 16, 2009—Invatec, Inc. (Bethlehem, PA) announced CE Mark approval of the In.Pact Falcon paclitaxel-eluting balloon catheter for percutaneous transluminal coronary angioplasty (PTCA).

Studies of Medtronic's CoreValve Presented

September 22, 2009—Medtronic, Inc. (Minneapolis, MN) announced that data on the Medtronic CoreValve percutaneous aortic valve system were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco.

TCT Presents Studies of Medtronic's CoreValve

September 22, 2009—Medtronic, Inc. (Minneapolis, MN) announced that data on the Medtronic CoreValve percutaneous aortic valve system were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco.

First-in-Human Implantation Performed With MValve's Transapical Mitral Valve Replacement System

October 5, 2015—MValve Technologies Ltd. announced the first-in-human implantation of its catheter-based transapical mitral valve replacement system.

CE Mark Approved for Medtronic's Recapturable CoreValve Evolut R System

September 3, 2014—Medtronic, Inc. announced European CE Mark approval for the 23-mm CoreValve Evolut R system for transcatheter aortic valve replacement (TAVR).

FORWARD Clinical Study Begins for Medtronic's Evolut R TAVR System in Real-World Setting

March 7, 2016—Medtronic plc announced that Prof.

Millipede Reports Successful First Use of Integrated ICE Delivery System for Iris Annuloplasty Ring

September 10, 2018—Millipede, Inc. announced the first use of its latest-generation delivery system, which incorporates a fully integrated intracardiac echocardiography (ICE) catheter.

FORWARD PRO Postmarket Study Will Evaluate Medtronic's CoreValve Evolut Pro TAVR System

September 21, 2017—Medtronic announced a new postmarket clinical study that will evaluate its CoreValve Evolut Pro transcatheter aortic valve replacement (TAVR) system in everyday clinical practice, including patients with severe symptomatic aortic stenosis at an intermediate, high, or extreme risk for open heart surgery.

Real-World Data Presented for Medtronic's Next-Generation CoreValve Evolut R TAVR Device

October 31, 2016—Medtronic plc announced the presentation of new data from two large registries that are evaluating 30-day clinical performance outcomes for the company’s self-expanding, recapturable, and repositionable CoreValve Evolut R transcatheter aortic valve replacement system in real-world severe aortic stenosis patient populations.

Medtronic's CoreValve Evolut R System Receives CE Mark Approval for Intermediate-Risk Aortic Stenosis Patients

August 1, 2016—Medtronic plc announced European CE Mark approval for the self-expanding, recapturable, and repositionable CoreValve Evolut R transcatheter aortic valve replacement system to treat aortic stenosis patients who are at intermediate risk for open-heart surgery as determined by a heart team.